air pollution;
mortality;
particulate matter;
dose-response;
distributed lag model;
US CITIES;
MORTALITY;
D O I:
10.1016/j.envres.2007.01.009
中图分类号:
X [环境科学、安全科学];
学科分类号:
08 ;
0830 ;
摘要:
The majority of studies that have investigated the relationship between particulate matter (PM) air pollution and mortality have assumed a linear dose-response relationship and have used either a single-day's PM or a 2- or 3-day moving average of PM as the measure of PM exposure. Both of these modeling choices have come under scrutiny in the literature, the linear assumption because it does not allow for non-linearities in the dose-response relationship, and the use of the single- or multi-day moving average PM measure because it does not allow for differential PM-mortality effects spread over time. These two problems have been dealt with on a piecemeal basis with non-linear dose-response models used in some studies and distributed lag models (DLMs) used in others. In this paper, we propose a method for investigating the shape of the PM-mortality dose-response relationship that combines a non-linear dose-response model with a DLM. This combined model will be shown to produce satisfactory estimates of the PM-mortality dose-response relationship in situations where non-linear dose response models and DLMs alone do not; that is, the combined model did not systemically underestimate or overestimate the effect of PM on mortality. The combined model is applied to ten cities in the US and a pooled dose-response model formed. When fitted with a change-point value of 60 mu g/m(3), the pooled model provides evidence for a positive association between PM and mortality. The combined model produced larger estimates for the effect of PM on mortality than when using a non-linear dose-response model or a DLM in isolation. For the combined model, the estimated percentage increase in mortality for PM concentrations of 25 and 75 mu g/m(3) were 3.3% and 5.4%, respectively. In contrast, the corresponding values from a DLM used in isolation were 1.2% and 3.5%, respectively. (C) 2007 Elsevier Inc. All rights reserved.
机构:
Nihon Univ, Sch Med, Dept Biomed Sci, Div Pharmacol, Oyaguchi Kamicho 30-1,Itabashi Ku, Tokyo, Japan
Nihon Univ, Sch Med, Clin Trials Res Ctr, Div Genom Epidemiol & Clin Trials, Itabashi Ku, Tokyo, JapanNihon Univ, Sch Med, Dept Biomed Sci, Div Pharmacol, Oyaguchi Kamicho 30-1,Itabashi Ku, Tokyo, Japan
Nagashima, Takuya
Minagawa, Kimino
论文数: 0引用数: 0
h-index: 0
机构:
Nihon Univ, Sch Med, Clin Trials Res Ctr, Div Genom Epidemiol & Clin Trials, Itabashi Ku, Tokyo, JapanNihon Univ, Sch Med, Dept Biomed Sci, Div Pharmacol, Oyaguchi Kamicho 30-1,Itabashi Ku, Tokyo, Japan
Minagawa, Kimino
Hayakawa, Takashi
论文数: 0引用数: 0
h-index: 0
机构:
Nihon Univ, Sch Med, Dept Biomed Sci, Div Pharmacol, Oyaguchi Kamicho 30-1,Itabashi Ku, Tokyo, Japan
Nihon Univ, Sch Med, Clin Trials Res Ctr, Div Genom Epidemiol & Clin Trials, Itabashi Ku, Tokyo, JapanNihon Univ, Sch Med, Dept Biomed Sci, Div Pharmacol, Oyaguchi Kamicho 30-1,Itabashi Ku, Tokyo, Japan
Hayakawa, Takashi
Takahashi, Yasuo
论文数: 0引用数: 0
h-index: 0
机构:
Nihon Univ, Sch Med, Clin Trials Res Ctr, Div Genom Epidemiol & Clin Trials, Itabashi Ku, Tokyo, JapanNihon Univ, Sch Med, Dept Biomed Sci, Div Pharmacol, Oyaguchi Kamicho 30-1,Itabashi Ku, Tokyo, Japan
Takahashi, Yasuo
Asai, Satoshi
论文数: 0引用数: 0
h-index: 0
机构:
Nihon Univ, Sch Med, Dept Biomed Sci, Div Pharmacol, Oyaguchi Kamicho 30-1,Itabashi Ku, Tokyo, Japan
Nihon Univ, Sch Med, Clin Trials Res Ctr, Div Genom Epidemiol & Clin Trials, Itabashi Ku, Tokyo, JapanNihon Univ, Sch Med, Dept Biomed Sci, Div Pharmacol, Oyaguchi Kamicho 30-1,Itabashi Ku, Tokyo, Japan
Asai, Satoshi
PHARMACOLOGY RESEARCH & PERSPECTIVES,
2025,
13
(01):
机构:
Nihon Univ, Sch Med, Dept Biomed Sci, Div Pharmacol, Oyaguchi Kamicho 30-1,Itabashi Ku, Tokyo, Japan
Nihon Univ, Sch Med, Clin Trials Res Ctr, Div Genom Epidemiol & Clin Trials, Itabashi Ku, Tokyo, JapanNihon Univ, Sch Med, Dept Biomed Sci, Div Pharmacol, Oyaguchi Kamicho 30-1,Itabashi Ku, Tokyo, Japan
Nagashima, Takuya
Minagawa, Kimino
论文数: 0引用数: 0
h-index: 0
机构:
Nihon Univ, Sch Med, Clin Trials Res Ctr, Div Genom Epidemiol & Clin Trials, Itabashi Ku, Tokyo, JapanNihon Univ, Sch Med, Dept Biomed Sci, Div Pharmacol, Oyaguchi Kamicho 30-1,Itabashi Ku, Tokyo, Japan
Minagawa, Kimino
Hayakawa, Takashi
论文数: 0引用数: 0
h-index: 0
机构:
Nihon Univ, Sch Med, Dept Biomed Sci, Div Pharmacol, Oyaguchi Kamicho 30-1,Itabashi Ku, Tokyo, Japan
Nihon Univ, Sch Med, Clin Trials Res Ctr, Div Genom Epidemiol & Clin Trials, Itabashi Ku, Tokyo, JapanNihon Univ, Sch Med, Dept Biomed Sci, Div Pharmacol, Oyaguchi Kamicho 30-1,Itabashi Ku, Tokyo, Japan
Hayakawa, Takashi
Takahashi, Yasuo
论文数: 0引用数: 0
h-index: 0
机构:
Nihon Univ, Sch Med, Clin Trials Res Ctr, Div Genom Epidemiol & Clin Trials, Itabashi Ku, Tokyo, JapanNihon Univ, Sch Med, Dept Biomed Sci, Div Pharmacol, Oyaguchi Kamicho 30-1,Itabashi Ku, Tokyo, Japan
Takahashi, Yasuo
Asai, Satoshi
论文数: 0引用数: 0
h-index: 0
机构:
Nihon Univ, Sch Med, Dept Biomed Sci, Div Pharmacol, Oyaguchi Kamicho 30-1,Itabashi Ku, Tokyo, Japan
Nihon Univ, Sch Med, Clin Trials Res Ctr, Div Genom Epidemiol & Clin Trials, Itabashi Ku, Tokyo, JapanNihon Univ, Sch Med, Dept Biomed Sci, Div Pharmacol, Oyaguchi Kamicho 30-1,Itabashi Ku, Tokyo, Japan
Asai, Satoshi
PHARMACOLOGY RESEARCH & PERSPECTIVES,
2025,
13
(01):